Genzyme Sets Sights On 13 Drug Approvals By 2012

To reach a goal of compound annual growth of 20 percent in the five-year period from 2006 to 2011, Genzyme will rely on new products and label expansions to drive growth, CEO Henri Termeer said during the company's annual analyst and investor day May 7